A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
Public ClinicalTrials.gov record NCT02326272. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Study identification
- NCT ID
- NCT02326272
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Industry
- Enrollment
- 227 participants
Conditions and interventions
Conditions
Interventions
- Certolizumab Pegol Biological
- Placebo Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 14, 2014
- Primary completion
- Jan 4, 2016
- Completion
- Sep 11, 2018
- Last update posted
- Oct 2, 2019
2014 – 2018
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ps0002 203 | Phoenix | Arizona | 85032 | — |
| Ps0002 214 | Bakersfield | California | 93309 | — |
| Ps0002 212 | Santa Monica | California | 90404 | — |
| Ps0002 204 | Ormond Beach | Florida | 32174 | — |
| Ps0002 207 | Portsmouth | New Hampshire | 03801 | — |
| Ps0002 202 | East Windsor | New Jersey | 08520 | — |
| Ps0002 210 | New York | New York | 10025 | — |
| Ps0002 206 | Rochester | New York | 14623 | — |
| Ps0002 209 | Wilmington | North Carolina | 28405 | — |
| Ps0002 205 | Cleveland | Ohio | 44106 | — |
| Ps0002 200 | Portland | Oregon | 97223 | — |
| Ps0002 201 | Greer | South Carolina | 29650 | — |
| Ps0002 208 | San Antonio | Texas | 78213 | — |
| Ps0002 213 | Richmond | Virginia | 23294 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02326272, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 2, 2019 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02326272 live on ClinicalTrials.gov.